Compare DexCom, Inc. (DXCM) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gap Inc — how do they compare? DexCom, Inc. trades at $89.32 (market cap $33.79B), while Gap Inc trades at $20.48 (market cap $7.55B). The key difference: DexCom, Inc. is far larger — about 4.5× Gap Inc's market cap, and Gap Inc pays a 3.34% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GAP | |
|---|---|---|
Market Cap | $33.79B | $7.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $29.13 |
52-Week Low | $54.84 | $18.35 |
Enterprise Value | $33.24B | $10.63B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Gap Inc. (GAP) trades at $21.51, up 5.08% today, showing strong momentum amid a bullish technical outlook. The stock presents compelling value with a P/E of 8.32 and P/S of 0.52, well below industry averages. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $0.38 exceeding estimates. Revenue growth has stabilized at $15.1B for 2025, while net income margin improved to 5.59%. The company maintains solid cash flow generation with $464M net cash flow in 2025.
Gap offers attractive valuation upside with a consensus price target of $26.09 (21% potential). However, risks include ongoing investigations by Pomerantz Law Firm and competitive pressures in retail. The turnaround story appears credible with nine consecutive positive comps, but execution risks remain. Current technical indicators suggest the stock is approaching overbought territory with RSI above 70.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
